These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25063383)

  • 41. Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the Art.
    de Castro MJ; Del Toro M; Giugliani R; Couce ML
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy for mucopolysaccharidosis VI: (Maroteaux-Lamy syndrome) present status and prospects.
    Giugliani R; Herber S; Lapagesse L; de Pinto C; Baldo G
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():152-8. PubMed ID: 25345097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Possible strategies to cross the blood-brain barrier.
    Bellettato CM; Scarpa M
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):131. PubMed ID: 30442184
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enzyme replacement therapy: efficacy and limitations.
    Concolino D; Deodato F; Parini R
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):120. PubMed ID: 30442189
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.
    Peck SH; Casal ML; Malhotra NR; Ficicioglu C; Smith LJ
    Mol Genet Metab; 2016 Aug; 118(4):232-43. PubMed ID: 27296532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Animal models for mucopolysaccharidoses and their clinical relevance.
    Haskins M; Casal M; Ellinwood NM; Melniczek J; Mazrier H; Giger U
    Acta Paediatr Suppl; 2002; 91(439):88-97. PubMed ID: 12572849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gene therapies for mucopolysaccharidoses.
    Rossi A; Brunetti-Pierri N
    J Inherit Metab Dis; 2024 Jan; 47(1):135-144. PubMed ID: 37204267
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future.
    Chen HH; Sawamoto K; Mason RW; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Tomatsu S
    J Hum Genet; 2019 Nov; 64(11):1153-1171. PubMed ID: 31455839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age.
    Megens JH; de Wit M; van Hasselt PM; Boelens JJ; van der Werff DB; de Graaff JC
    Paediatr Anaesth; 2014 May; 24(5):521-7. PubMed ID: 24612129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system.
    Kim KH; Dodsworth C; Paras A; Burton BK
    Mol Genet Metab; 2013 Aug; 109(4):382-5. PubMed ID: 23845234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.
    Shapiro EG; Jones SA; Escolar ML
    Mol Genet Metab; 2017 Dec; 122S():1-7. PubMed ID: 29074036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cell cycle disturbances in mucopolysaccharidoses: Transcriptomic and experimental studies on cellular models.
    Brokowska J; Gaffke L; Pierzynowska K; Cyske Z; Węgrzyn G
    Exp Biol Med (Maywood); 2022 Sep; 247(18):1639-1649. PubMed ID: 36000158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mucopolysaccharidosis and Autophagy: Controversies on the Contribution of the Process to the Pathogenesis and Possible Therapeutic Applications.
    Pierzynowska K; Gaffke L; Podlacha M; Brokowska J; Węgrzyn G
    Neuromolecular Med; 2020 Mar; 22(1):25-30. PubMed ID: 31372809
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses.
    Cotugno G; Tessitore A; Capalbo A; Annunziata P; Strisciuglio C; Faella A; Aurilio M; Di Tommaso M; Russo F; Mancini A; De Leonibus E; Aloj L; Auricchio A
    Hum Gene Ther; 2010 May; 21(5):555-69. PubMed ID: 20021231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycan-based biomarkers for mucopolysaccharidoses.
    Lawrence R; Brown JR; Lorey F; Dickson PI; Crawford BE; Esko JD
    Mol Genet Metab; 2014 Feb; 111(2):73-83. PubMed ID: 23958290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses.
    Rapoport DM; Mitchell JJ
    Mol Genet Metab; 2017 Dec; 122S():49-54. PubMed ID: 28964643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of disease severity in mucopolysaccharidoses.
    Beck M; Muenzer J; Scarpa M
    J Pediatr Rehabil Med; 2010; 3(1):39-46. PubMed ID: 21791828
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies.
    de Ruijter J; Valstar MJ; Wijburg FA
    Curr Pharm Biotechnol; 2011 Jun; 12(6):923-30. PubMed ID: 21235449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Mucopolysaccharidoses--biochemical mechanisms of diseases and therapeutic possibilities].
    Kloska A; Tylki-Szymańska A; Wegrzyn G
    Postepy Biochem; 2011; 57(2):133-47. PubMed ID: 21913414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.